New Agents for Heart Failure: Sacubitril/Valsartan
Sacubitril/valsartan is a combination neprilysin inhibitor/angiotensin receptor blocker that significantly reduces the risk of all-cause death, cardiovascular death, and heart failure hospitalization, while improving related symptoms
▶︎
New Agents for Heart Failure: Ivabradine
▶︎
PARADIGM-HF — The Experts’ Discussion
▶︎
Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction
▶︎
Entresto (Sacubitril / Valsartan) Explained, the Good and the Bad: Side Effects and How I Use it.
▶︎
Entresto
▶︎
Pearls and Pitfalls in the Management of CHF
▶︎
Professor Milton Packer - 'Heart failure – are there limits to anti-diabetic therapy with SGLT2'
▶︎
Paradigm Heart Failure Presentation - Lisa M. Mielniczuk, MD
▶︎
Update on Novel Therapies for Heart Failure (Milton Packer, MD) February, 10, 2017
▶︎
SGLT2 Inhibitors and Heart Failure
▶︎
Sacubitril/Valsartan (Entresto®) - The Core Four
▶︎
Managing Heart Failure – Michelle M. Kittleson, MD, PhD - 2020 Healing the Heart
▶︎
Heart failure: BNP
▶︎
Heart Failure with Preserved Ejection Fraction: Five Common Myths - Grand Rounds with James Fang, MD
▶︎
Entresto - Is It Really A Miracle Drug?
▶︎
PARADIGM HF/ Entresto | the real Evidence Based Medicine perspective
▶︎
Chronic Management of Heart Failure: A Guideline Approach (Myung Park, MD)
▶︎
Legacy Health Use of ARNI and SGLT 2 Inhibitors in Systolic CHF
▶︎
Sacubitril/Valsartan: Should We Reshuffle the Deck in the Treatment of HF?
▶︎